Lilly Pumps $1.8B into Indianapolis Pharma Expansion, Boosting Jobs

INDIANAPOLIS — Eli Lilly and Company, the Indianapolis-based pharmaceutical giant, announced a $1.8 billion investment to upgrade its manufacturing operations at the Lilly Technology Center in the city. The project expands existing capabilities and establishes new production lines to meet surging demand for innovative medicines, according to the Indiana Business Journal. CEO David Ricks hailed Lilly's broader U.S. strategy as 'the largest pharmaceutical expansion investment in U.S. history' during a Washington, D.C., press conference, where the company unveiled a $27 billion plan for four new 'mega sites' set to create over 3,000 jobs nationwide.

This Indianapolis initiative builds on Lilly's aggressive growth in Indiana, including a $9 billion commitment at its newest site in Lebanon, 30 miles northwest of the capital. Located in the LEAP Research and Innovation District, the Lebanon facility — where ground was broken in April 2023 — will add 200 full-time jobs for scientists and engineers, bringing total employment to 900 when fully operational by 2028. State officials are partnering with Lilly on infrastructure and workforce training to support the 600-acre complex, which begins medicine production by late 2026.

Lilly's Indiana investments since 2020 exceed $18 billion when combined with U.S. and European sites, including $5.3 billion and $4.5 billion for Lebanon expansions last year. The company's pipeline, featuring blockbuster drugs like tirzepatide, drives these moves amid global supply pressures. Indianapolis, home to Lilly's headquarters, solidifies its status as the epicenter of the firm's domestic manufacturing surge.